

05-16-02

GP1623

TRANSMITTAL LETTER		Case No. 10466/140
Serial No. 09/944,929	Filing Date August 31, 2001	Examiner To be assigned
Inventor(s) Ashkenazi et al		Group Art Unit 1623
Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME		

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an Information Disclosure Statement, Form PTO-1449, 2 cited references, Statement regarding Relevant Priority Documents and return postcard

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below.

RECEIVED
TECH CENTER - BCU 2900


	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity	
Rate	Add'l Fee
x \$9=	
x 42=	
+\$140=	
Total add'l fee	\$

Other Than Small Entity	
Rate	Add'l Fee
x \$18=	
x \$84=	
+\$280=	
Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$_____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted, *


Gregory M. Zink, Ph.D.
Registration No. 48,492
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, Express Mail Label No. EL 448312697US with sufficient postage, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 5/15/02


Date

5/14/02

Signature



rev. Dec -00
Document 2



"Express Mail" mailing label number

Date of Deposit

9/15/02

Our Case No.: 10466/140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ashkenazi et al.

Serial No.: 09/944,929

Filing Date: August 31, 2001

For: SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME

Examiner: To be assigned

Group Art Unit No.: 1623

RECEIVED
TECH CENTER 1600 2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

OTHER ART


1. Blast Results A1-A31, GenBank
2. Blast Results, B1-B7, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,




Gregory M. Zinkl, Ph.D.
Registration No. 48,492
Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200

"Express Mail" mailing label number EL 448312697US

Date of Deposit 5/15/02



Our Case No. 10466/140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Ashkenazi et al.)
) Examiner To be assigned
Serial No. 09/944,929)
) Group Art Unit No. 1623
Filing Date: August 31, 2001)
)
For SECRETED AND)
TRANSMEMBRANE)
POLYPEPTIDES AND NUCLEIC)
ACIDS ENCODING THE SAME)

RELEVANT PRIORITY DOCUMENTS

Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

The following priority documents are relevant to the presently claimed invention:

1. 60/075945; filed 2/25/1998
2. PCT/US98/25108; filed 12/1/1998
3. 09/254311; filed 3/3/1999
4. PCT/US99/28301; filed 12/1/1999

5. PCT/US00/05841; filed 3/2/2000
6. PCT/US00/08439; filed 3/30/2000
7. 09/866028; filed 5/25/2001

Respectfully submitted,



Gregory M. Zinkl, Ph.D.
Registration No. 48,492
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200